2023. Gut Microbiota Metabolites As A New Therapeutic Target In Patients With Coronary Artery Disease And Atrial Fibrillation. Journal of Pharmaceutical Negative Results. (Jan. 2023), 1221–1227. DOI:https://doi.org/10.47750/pnr.2023.14.02.157.